|
WHO Adolescent HTC Review Update (PO# 200660799) |
George Rutherford, MD |
Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, South Sudan, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Central African Republic, Chad, Congo (Kinshasa), Congo (Brazzaville), Equatorial Guinea, Gabon, Sao Tome and Principe, Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, Western Sahara, Botswana, Lesotho, Namibia, South Africa, Swaziland, Western Africa, Benin, Burkina Faso, Cape Verde, Ivory Coast, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, China, Hong Kong S.A.R., China, North Korea, Japan, Macao S.A.R., China, Mongolia, Afghanistan, Bangladesh, Bhutan, India, Iran, Maldives, Nepal, Pakistan, Sri Lanka, Brunei, Indonesia, Viet Nam, Laos, Malaysia, Myanmar, Singapore, Thailand, Timor-Leste, Philippines, Armenia, Azerbaijan, Bahrain, Cyprus, Georgia, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Palestinian Territory, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates, Yemen, Albania, Andorra, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Jersey, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela, Anguilla, Turks and Caicos Islands, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Guadeloupe, Haiti, Jamaica, Martinique, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Bermuda, Canada, Greenland, U.S. Virgin Islands, American Samoa, Northern Mariana Islands, Australia, Cook Islands, Guam, French Polynesia, Fiji, Kiribati, Marshall Islands, Micronesia, Nauru, New Zealand, Niue, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu |
|
|
|
San Francisco National Clinical Trial Center, ESPIRIT |
Steven Deeks, MD |
Morocco, Japan, Singapore, Thailand, Israel, Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Spain, United Kingdom, Argentina, Brazil, Canada, Australia |
|
|
|
Protocol AI463-189-004: A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) |
|
China, South Korea, India, Israel, Poland, Romania, Russia, United Kingdom |
|
|
|
Office of the UN Special Envoy for Tuberculosis |
Eric Goosby, MD |
Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, South Sudan, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Central African Republic, Chad, Congo (Kinshasa), Congo (Brazzaville), Equatorial Guinea, Gabon, Sao Tome and Principe, Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, Western Sahara, Botswana, Lesotho, Namibia, South Africa, Swaziland, Benin, Burkina Faso, Cape Verde, Ivory Coast, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo, Central Asia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, China, Hong Kong S.A.R., China, North Korea, South Korea, Macao S.A.R., China, Mongolia, Afghanistan, Bangladesh, Bhutan, India, Iran, Maldives, Nepal, Sri Lanka, Brunei, Cambodia, Indonesia, Viet Nam, Laos, Malaysia, Myanmar, Singapore, Thailand, Timor-Leste, Philippines, Armenia, Azerbaijan, Bahrain, Cyprus, Georgia, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Palestinian Territory, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates, Yemen, Albania, Andorra, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Jersey, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Bolivia, Brazil, Chile, Colombia, Ecuador, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela, Caribbean, Anguilla, Turks and Caicos Islands, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Guadeloupe, Haiti, Jamaica, Martinique, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Bermuda, Canada, Greenland, U.S. Virgin Islands, American Samoa, Northern Mariana Islands, Australia, Cook Islands, Guam, French Polynesia, Fiji, Kiribati, Marshall Islands, Micronesia, Nauru, New Zealand, Niue, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu |
|
|
|
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26- Year-Old Men and 16- to 26- Year-Old Women |
Joel Palefsky, MD |
South Africa, Malaysia, Thailand, Israel, Turkey, Denmark, Germany, Norway, Poland, Spain, Sweden, Mexico, Colombia, Peru, Canada |
|
|